AbbVie's Skyrizi Hits Goals in Ulcerative Colitis Study
March 23 2023 - 9:26AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. on Thursday said a Phase 3 induction study of its
blockbuster psoriasis drug Skyrizi met the key goals in adults with
the chronic inflammatory bowel disease ulcerative colitis.
The North Chicago, Ill., biopharmaceutical company said Skyrizi
met the primary endpoint of clinical remission, along with all
secondary endpoints, in adults with moderately to severely active
ulcerative colitis.
AbbVie said 20.3% of patients receiving Skyrizi in the study
achieved clinical remission, compared to 6.2% of patients receiving
placebo, adding that it saw no new safety risks.
AbbVie reported global revenue of nearly $5.2 billion last year
for Skyrizi, which is approved by in the U.S. and Europe for the
treatment of plaque psoriasis, psoriatic arthritis and Crohn's
disease.
AbbVie is relying on Skyrizi and fellow blockbuster autoimmune
drug Rinvoq to make up for lost sales for its mega-blockbuster
Humira, the highest-grossing drug of all time that faces the end of
U.S. patent protection this year.
AbbVie earlier this year raised its 2025 risk-adjusted sales
target for Rinvoq and Skyrizi to more than $17.5 billion, including
more than $10 billion for Skyrizi.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 23, 2023 09:11 ET (13:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2024 to May 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2023 to May 2024
